Total Payments
$581,179
2024 Payments
$111,709
Companies
35
Transactions
453
Medicare Patients
1,360
Medicare Billing
$186,757
Payment Breakdown by Category
Other$286,093 (49.2%)
Consulting$250,359 (43.1%)
Travel$32,768 (5.6%)
Food & Beverage$6,685 (1.2%)
Research$4,880 (0.8%)
Education$394.44 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $276,741 | 135 | 47.6% |
| Consulting Fee | $250,359 | 96 | 43.1% |
| Travel and Lodging | $32,768 | 77 | 5.6% |
| Honoraria | $9,353 | 6 | 1.6% |
| Food and Beverage | $6,685 | 128 | 1.2% |
| Unspecified | $4,880 | 6 | 0.8% |
| Education | $394.44 | 5 | 0.1% |
Payments by Type
General
$576,299
447 transactions
Research
$4,880
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $114,016 | 69 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $59,686 | 45 | $0 (2024) |
| ADC Therapeutics America, Inc. | $58,922 | 23 | $0 (2024) |
| Kite Pharma, Inc. | $51,141 | 44 | $0 (2024) |
| BeiGene USA, Inc. | $44,977 | 26 | $0 (2024) |
| Genentech USA, Inc. | $34,519 | 30 | $0 (2024) |
| Kyowa Kirin, Inc. | $31,085 | 32 | $0 (2023) |
| Seagen Inc. | $27,455 | 24 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $19,730 | 10 | $0 (2024) |
| Celgene Corporation | $16,847 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $111,709 | 68 | Incyte Corporation ($34,206) |
| 2023 | $83,212 | 48 | ADC Therapeutics America, Inc. ($25,685) |
| 2022 | $94,357 | 70 | Incyte Corporation ($19,926) |
| 2021 | $99,599 | 73 | Incyte Corporation ($37,434) |
| 2020 | $70,331 | 48 | Incyte Corporation ($17,530) |
| 2019 | $74,433 | 75 | Celgene Corporation ($14,747) |
| 2018 | $30,186 | 44 | AstraZeneca Pharmaceuticals LP ($9,016) |
| 2017 | $17,350 | 27 | Gilead Sciences Inc ($8,354) |
All Payment Transactions
453 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: Oncology | ||||||
| 12/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $962.01 | General |
| Category: Oncology | ||||||
| 12/18/2024 | ADC Therapeutics America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,840.00 | General |
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,870.00 | General |
| Category: Oncology | ||||||
| 12/14/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,004.00 | General |
| 12/12/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $123.66 | General |
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 12/06/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $119.66 | General |
| 12/05/2024 | Genentech USA, Inc. | Polivy (Biological), Lunsumio, Columvi | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Polivy (Biological), Lunsumio, Columvi | Food and Beverage | In-kind items and services | $82.59 | General |
| Category: BioOncology | ||||||
| 12/03/2024 | ADC Therapeutics America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,840.00 | General |
| 11/27/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,757.00 | General |
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,447.00 | General |
| 11/12/2024 | Incyte Corporation | MONJUVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $4,920.00 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Incyte Corporation | MONJUVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,110.00 | General |
| Category: Oncology | ||||||
| 11/02/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $43.25 | General |
| Category: BioOncology | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $850.05 | General |
| 10/28/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $980.99 | General |
| Category: Oncology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,964.00 | General |
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,176.00 | General |
| 10/02/2024 | ADC Therapeutics America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,650.00 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,769.42 | Research |
| Study: Ph1b 2 TDB CHP Pola in NHL for dose escalation Ph1b followed by 1L DLBCL for expansion Ph2 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph1b 2 TDB CHP Pola in NHL for dose escalation Ph1b followed by 1L DLBCL for expansion Ph2 | F. Hoffmann-La Roche AG | $2,769 | 1 |
| Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | F. Hoffmann-La Roche AG | $1,175 | 4 |
| A study related to non-Hodgkin lymphoma, compares the efficacy of obinutizumab in combination with chemotherapy versus rituximab- based treatments for untreated advanced cases (CL-NHL-13648) | Celgene Corporation | $935.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 309 | 547 | $159,993 | $44,230 |
| 2022 | 5 | 331 | 622 | $176,875 | $50,489 |
| 2021 | 5 | 313 | 598 | $158,992 | $46,280 |
| 2020 | 7 | 407 | 732 | $186,932 | $45,758 |
Total Patients
1,360
Total Services
2,499
Medicare Billing
$186,757
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 163 | 290 | $71,340 | $18,849 | 26.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 84 | 136 | $47,464 | $13,539 | 28.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 79 | $23,463 | $7,052 | 30.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 31 | 31 | $15,779 | $4,127 | 26.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 11 | $1,947 | $662.53 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 162 | 326 | $79,615 | $22,340 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 77 | 118 | $41,182 | $12,963 | 31.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 119 | $35,343 | $9,479 | 26.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $15,779 | $4,151 | 26.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 26 | 28 | $4,956 | $1,555 | 31.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 167 | 340 | $83,452 | $23,609 | 28.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 85 | 124 | $43,276 | $13,934 | 32.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 25 | 98 | $20,580 | $5,534 | 26.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $8,144 | $2,190 | 26.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 20 | 20 | $3,540 | $1,012 | 28.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 184 | 360 | $87,996 | $20,244 | 23.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 96 | 160 | $54,847 | $13,546 | 24.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 36 | 113 | $23,730 | $6,248 | 26.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 19 | 19 | $9,671 | $2,378 | 24.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 18 | $5,346 | $1,459 | 27.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 17 | 18 | $3,186 | $1,026 | 32.2% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 41 | 44 | $2,156 | $857.13 | 39.8% |
About Amitkumar Mehta
Amitkumar Mehta is a Hematology & Oncology healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/23/2010. The National Provider Identifier (NPI) number assigned to this provider is 1003122573.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amitkumar Mehta has received a total of $581,179 in payments from pharmaceutical and medical device companies, with $111,709 received in 2024. These payments were reported across 453 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($276,741).
As a Medicare-enrolled provider, Mehta has provided services to 1,360 Medicare beneficiaries, totaling 2,499 services with total Medicare billing of $186,757. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Birmingham, AL
- Active Since 08/23/2010
- Last Updated 01/31/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1003122573
Products in Payments
- MONJUVI (Drug) $117,809
- CALQUENCE (Drug) $54,500
- BRUKINSA (Drug) $45,427
- Yescarta (Drug) $40,601
- ADCETRIS (Biological) $38,936
- POTELIGEO (Drug) $25,766
- Revlimid (Drug) $13,760
- Columvi (Biological) $12,442
- IMBRUVICA (Drug) $10,849
- Zydelig (Drug) $9,354
- Tecartus (Drug) $7,950
- Imbruvica (Drug) $7,169
- Folotyn (Drug) $4,541
- clonoSEQ (Device) $4,450
- KYMRIAH (Biological) $4,258
- LUMOXITI (Biological) $4,110
- OPDIVO (Biological) $4,025
- Rituxan (Biological) $3,960
- POLIVY (Biological) $3,800
- Venclexta (Biological) $3,800
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Birmingham
Dr. Khaleel Ashraf, M.d, M.D
Hematology & Oncology — Payments: $628,093
Hematology & Oncology $628,093
Luciano Costa
Hematology & Oncology — Payments: $447,833
Hematology & Oncology $447,833
Dr. Michael Birrer, M.d. Ph.d, M.D. PH.D
Hematology & Oncology — Payments: $432,657
Hematology & Oncology $432,657
Pankit Vachhani, Md, MD
Hematology & Oncology — Payments: $405,357
Hematology & Oncology $405,357
Robert Conry, Md, MD
Hematology & Oncology — Payments: $219,082
Hematology & Oncology $219,082
Dr. Mayur Narkhede, M.d, M.D
Hematology & Oncology — Payments: $205,834
Hematology & Oncology $205,834